ELVN
Enliven Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website enliventherapeutics.com
- Employees(FY) 44
- ISIN US29337E1029
Performance
-2.62%
1W
-17.85%
1M
+3.43%
3M
+13.61%
6M
+71.89%
YTD
+118.86%
1Y
Profile
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. Enliven Therapeutics, Inc. is headquartered in Boulder, Colorado.
Technical Analysis of ELVN 2024-12-10
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-11-13 16:05
- 2024-11-13 03:05
- 2024-11-07 16:05
- 2024-11-07 03:05
- 2024-10-31 08:50
- 2024-10-18 16:38
Why this largely unknown company is one analyst's top biotech pick(Yahoo Finance Video)
- 2024-10-03 21:00
- 2024-09-30 04:52
Enliven Therapeutics’ ELVN-001 shows promise in Phase I CML trial(Clinical Trials Arena)
- 2024-09-28 09:35
- 2024-09-27 21:35
- 2024-09-26 08:50
- 2024-09-18 16:05
- 2024-09-18 04:05
- 2024-09-09 14:05
- 2024-09-04 09:55
- 2024-09-03 17:49
- 2024-08-24 09:08
- 2024-08-16 09:55
- 2024-08-13 16:05
- 2024-08-13 04:05
- 2024-07-16 17:44
- 2024-06-27 16:47
- 2024-05-29 16:05
- 2024-05-29 04:05
- 2024-05-20 17:06
- 2024-05-14 17:01
Enliven Therapeutics Q1 Loss Narrows(MT Newswires)
- 2024-05-14 16:05
- 2024-05-14 10:54
- 2024-05-14 04:05
- 2024-04-19 15:03
Page 1 of 2
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.